A Deep Dive Into the Investigational Alzheimer’s Drug Donanemab | LiveTalk | Being Patient

Поділитися
Вставка
  • Опубліковано 26 гру 2024

КОМЕНТАРІ • 3

  • @bathsheba9581
    @bathsheba9581 2 роки тому +3

    Beta amyloid plaque is not the problem. When I reviewed the "nun's study", I came to the conclusion that our researchers were on the wrong path and have remained on this misguided path for many years now. I guess they've realized it now and they seem truly lost and disoriented with the new understanding.

    • @polsen114
      @polsen114 2 роки тому +1

      Do you know what the right path is?

    • @Golgispot
      @Golgispot 10 місяців тому

      In the land of the blind, the one-eyed man is king. I have ADz, I will take the best available now and hope for better in future.